The $10 million investment will add 3760 square feet of production space to the current facility, providing added flexibility and capacity to the CDMO and its clients.
The expansion consists of three new rooms: one dispensing/flex room, one tablet press room and one flex room to accommodate the company’s growing portfolio of commercial services following sustained increase in demand from clients for high potent handling capabilities.
New equipment also forms part of the investment and includes a Fette FE55 tablet press, a Bosch 720 encapsulator, which both offer containment capabilities for the safe handling of potent products, and a weigh and dispense isolator.
“The new equipment we’ve purchased is ideal for the small batch size and high changeover products which our clients require,” said John Ross, President at Mayne Pharma US and Metrics Contract Services. “Our clients will see immediate benefits through higher yields and improved potent handling.”
“We recognised that customer’s commercial requirements often demanded increased flexibility within production suites. This expansion will cater for those needs because it creates more spaces where equipment trains can be tailored to the applicable process.”
The expansion project which has been in development during the last 6 months is expected to be complete and fully operational by February 2021.
Ross added: “This is a significant investment for the business and reflects our commitment to increasing our novel oral solid manufacturing capabilities and providing our clients with quality services from initial concept through to global commercialisation.”
“We are now actively looking at the next phase of investment and how to maximise the expanded facility even further with the potential addition of further packaging and adjacent formulation technologies.”
Metrics Contract Services offers quality pharmaceutical formulation development, clinical trial materials manufacturing for all phases, analytical method development and validation services and commercial scale manufacturing and specialises in highly potent, novel oral solid dosage forms.